Text Size
Trial record 12 of 1957 for:    Open Studies | "Hematologic Diseases"
Previous Study | Return to List | Next Study

Progression of Hematopoietic Diseases in Shanghai, China

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by University of Colorado, Denver.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Information provided by:
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00365014
First received: August 14, 2006
Last updated: May 23, 2007
Last verified: May 2007
History of Changes
  Purpose

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.


Condition
Hematologic Diseases

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Estimated Enrollment: 10757
Study Start Date: August 2003
Estimated Study Completion Date: April 2008
Detailed Description:

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00365014

Contacts
Contact: Sherilyn A. Gross, PhD 303-315-1659 Sherilyn.gross@uchsc.edu

Locations
China
Joint Sino-US Clinical and Molecular Laboratory (JCML) Recruiting
Shanghai, China, 200032
Sponsors and Collaborators
University of Colorado, Denver
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Investigators
Principal Investigator: Richard D Irons, PhD University of Colorado at Denver and Health Sciences Ctr.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00365014     History of Changes
Other Study ID Numbers: 02-036
Study First Received: August 14, 2006
Last Updated: May 23, 2007
Health Authority: United States: Institutional Review Board
China: Ministry of Health

Keywords provided by University of Colorado, Denver:
aplastic anemia
myelodysplastic syndromes
cytopenias
 acute myeloid leukemia
myelodysplastic/myeloproliferative diseases
benzene poisoning

Additional relevant MeSH terms:
Hematologic Diseases
Anemia, Aplastic
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Myelodysplastic Syndromes
Preleukemia
 Anemia
Bone Marrow Diseases
Leukemia
Neoplasms by Histologic Type
Neoplasms
Precancerous Conditions

ClinicalTrials.gov processed this record on May 19, 2013